| Name | Peramivir Trihydrate |
| Description | Peramivir Trihydrate (RWJ-270201) is a neuraminidase inhibitor (IC50: 0.09 nM) which prevents normal processing of virus particles such that virus particles are not released from infected cells. Peramivir Trihydrate is a cyclopentane derivative with activity against influenza A and B viruses. |
| In vitro | When used in conjunction with favipiravir (20-40 mg/kg/day), peramivir (0.025-0.1 mg/kg/day) increases cell survival rates by 10-50%. At a dosage of 0.5 mg/kg/day, peramivir exhibits a protective effect against H1N1 in mice, covering about 30% of the virus. The combination of peramivir (1 mg/kg/day) with amantadine (5-10 mg/kg/day) results in weight losses of 1.69 and 0.69, respectively; however, for a sub-lethal influenza A (H3N2) virus model in mice, administering peramivir (3 mg/kg/day) alongside rimantadine (10-30 mg/kg/day) does not affect weight. At a higher concentration, peramivir (30 mg/kg) effectively extends the survival of mice infected with the systemically replicating H5N1 virus. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 6.6 mg/mL (17.26 mM), Sonication is recommended.
|
| Keywords | S021812 | S 021812 | RWJ-270201 Trihydrate | RWJ270201 Trihydrate | RWJ270201 | RWJ 270201 Trihydrate | RWJ 270201 | Peramivir Trihydrate | Peramivir | Inhibitor | inhibit | InfluenzaVirus | Influenza Virus | influenza viral neuraminidase | BCX-1812 Trihydrate | BCX1812 Trihydrate | BCX1812 | BCX 1812 Trihydrate | BCX 1812 |
| Inhibitors Related | Flubendazole | Esculin | Acetylcysteine | Fumaric acid | Nitazoxanide | Balsalazide disodium dihydrate | Curcumin | Niclosamide | Naringenin | Salcomine | Dihydromyricetin | β-Glycerophosphate disodium salt hydrate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | EMA Approved Drug Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library |
United States
